Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 1
2009 2
2010 1
2011 1
2012 2
2013 3
2014 2
2015 1
2018 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T, Komiyama S, Kigawa J, Tanabe H, Kato K, Itamochi H, Fujiwara H, Kamiura S, Hamano T, Sugiyama T; Japanese Gynecologic Oncology Group. Shoji T, et al. BMC Cancer. 2018 Jul 31;18(1):771. doi: 10.1186/s12885-018-4505-4. BMC Cancer. 2018. PMID: 30064406 Free PMC article. Clinical Trial.
Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R; Japanese Gynecologic Oncology Group. Susumu N, et al. Gynecol Oncol. 2008 Jan;108(1):226-33. doi: 10.1016/j.ygyno.2007.09.029. Epub 2007 Nov 9. Gynecol Oncol. 2008. PMID: 17996926 Clinical Trial.
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H, Aoki D, Michimae H, Mizuno M, Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, Tokunaga H, Matoda M, Nakanishi T, Watanabe Y, Takahashi F, Saito T, Yaegashi N; Japanese Gynecologic Oncology Group. Nomura H, et al. JAMA Oncol. 2019 Jun 1;5(6):833-840. doi: 10.1001/jamaoncol.2019.0001. JAMA Oncol. 2019. PMID: 30896757 Free PMC article. Clinical Trial.
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group. Katsumata N, et al. Lancet. 2009 Oct 17;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767092 Clinical Trial.
How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey.
Yokoyama Y, Ito K, Takamatsu K, Takehara K, Nakanishi T, Harano K, Watari H, Susumu N, Aoki D, Saito T; Disease Committee of Uterine Cancer, Japanese Gynecologic Oncology Group. Yokoyama Y, et al. Int J Clin Oncol. 2015 Oct;20(5):997-1004. doi: 10.1007/s10147-015-0808-5. Epub 2015 Mar 6. Int J Clin Oncol. 2015. PMID: 25744579
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group. Katsumata N, et al. Lancet Oncol. 2013 Sep;14(10):1020-6. doi: 10.1016/S1470-2045(13)70363-2. Epub 2013 Aug 13. Lancet Oncol. 2013. PMID: 23948349 Clinical Trial.
Surgical principles for managing stage IB2, IIA2, and IIB uterine cervical cancer (Bulky Tumors) in Japan: a survey of the Japanese Gynecologic Oncology Group.
Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, Matsumoto T, Kita T, Takizawa K; Disease Committee of Uterine Cervical and Vulvar Cancer, Japanese Gynecologic Oncology Group. Mikami M, et al. Int J Gynecol Cancer. 2014 Sep;24(7):1333-40. doi: 10.1097/IGC.0000000000000202. Int J Gynecol Cancer. 2014. PMID: 25078340
Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.
Toita T, Kato S, Ishikura S, Tsujino K, Kodaira T, Uno T, Hatano K, Sakurai H, Niibe Y, Kazumoto T, Nishimura T, Kitagawa R, Fukutani M, Oguchi M, Umayahara K, Hirashima Y, Aoki Y, Takizawa K; Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group. Toita T, et al. Int J Clin Oncol. 2011 Aug;16(4):379-86. doi: 10.1007/s10147-011-0196-4. Epub 2011 Feb 18. Int J Clin Oncol. 2011. PMID: 21331768
Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group.
Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, Matsumoto T, Kita T, Takizawa K; Disease Committee of Uterine Cervical and Vulvar Cancer, Japanese Gynecologic Oncology Group. Mikami M, et al. Int J Gynecol Cancer. 2013 Nov;23(9):1655-60; quiz 1661-2. doi: 10.1097/IGC.0000000000000005. Int J Gynecol Cancer. 2013. PMID: 24172100
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page